By Fineline Cube 
Shandong Boan Biotechnology Co., Ltd (HKG: 6955) announced on August 8, 2025, that its self-developed product, Boyouping (dulaglutide injection), has received marketing approval from China’s National Medical Products Administration (NMPA) for glycemic control in adults with type 2 diabetes.
Clinical and Commercial Advantages
Boyouping is the world’s first and currently the only approved biosimilar of Trulicity. It will be commercialized in mainland China through a partnership between Boan Biotech and Shanghai Pharmaceutical Holding Co., Ltd. (Shanghai Pharma).
Dulaglutide Mechanism and Benefits
Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist administered once a week. It improves pancreatic β-cell function and effectively lowers blood glucose and glycated hemoglobin (HbA1c) levels. Beyond glycemic control, dulaglutide offers multiple clinical benefits, including:
- Reduced risk of major adverse cardiovascular events
- Weight loss
- Kidney protection
- Low incidence of hypoglycemia
- Minimal gastrointestinal side effects
- Once-weekly dosing for improved patient convenience and adherence-Fineline Info & Tech